Current Heart Failure Reports

, Volume 15, Issue 4, pp 250–259 | Cite as

The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery

  • Luise Holzhauser
  • Gene Kim
  • Gabriel Sayer
  • Nir Uriel
Biomarkers of Heart Failure (W Tang and J Grodin, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Biomarkers of Heart Failure


Purpose of Review

Left ventricular assist device (LVAD) therapy serves as mainstay therapy for bridge to transplantation and destination therapy. Evidence is now mounting on the role of LVAD therapy as bridge to recovery. In the current review, we will summarize the data on biomarkers of myocardial recovery following LVAD implantation.

Recent Findings

Myocardial recovery can occur spontaneously, following pharmacological intervention and in the setting of mechanical circulatory support such as LVAD. Several biomarkers such as B-type natriuretic peptide (BNP), N-terminal pro B-type natriuretic peptide (NT-proBNP), ST2, etc. have been identified and are being used to guide medical therapy in heart failure (HF) patients. However, recent data raised concern that those biomarkers may not be helpful in managing heart failure patients in general, and as such questioned their use in the advanced heart failure population. At this point, the use of biomarker to identify patients with myocardial recovery during LVAD support has not been established, and LVAD explantation remains a decision driven by echocardiographic and hemodynamics improvement.


HF biomarkers in monitoring myocardial and neurohormonal activation response to mechanical unloading and medical therapy could be valuable. However, at this time, there is inadequate evidence to select a single or a set of HF biomarkers to reliably identify patients bridged to recovery for LVAD explantation.


Heart failure Biomarkers Left ventricular assist device (LVAD) Myocardial recovery 


Cardiac remodeling characterized by increase in chamber size, changes in shape, and reduction in function is largely driven by persistent volume and pressure overload and is the hallmark of cardiomyopathy and heart failure [1]. Medical therapy with neurohormonal blockade and electrical synchronization (CRT) has been shown to induce reverse remodeling and regression of those anatomical changes [2, 3, 4, 5, 6]. Lately, left ventricular assist device (LVAD) therapy demonstrated robust reverse remodeling probably through significant unloading of the left ventricle and was associated with myocardial recovery and the ability to explant the pump. Research has been focused on comparing paired myocardial tissue at the time of LVAD implantation and later at the time of transplantation [7, 8, 9, 10, 11] analyzing the molecular changes accompanying the reverse remodeling process. However, the clinical dilemma still remains, which patients recover their myocardium to a level that will safely sustain LVAD explantation. Several investigators assessed the role of heart failure biomarkers to monitor and potentially identify patients with myocardial recovery. This review will summarize current knowledge on the role of biomarkers in diagnosing HF, monitoring and predicting outcome, and how or if to apply these findings on the advanced heart failure population supported with LVAD.

LVAD as Bridge to Recovery

To date, LVAD bridge to recovery (BTR) studies have revealed very large differences in the rate of defined recovery ranging from 4.5 to 73% depending on patient population with respect to etiology and duration of heart failure as well as patient age and gender [12].

In the overall LVAD population, myocardial recovery is a rare phenomenon. Topkara et al. reported that in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), the overall rate of myocardial recovery was only 1.4% [13]. Similar to this finding, Wever-Pinzon reported that among 15,138 INTERMACS patients, cardiac recovery occurred in 192 (1.3%). However, the incidence of myocardial recovery was significantly higher among patients with a priori BTR strategy (11.2%) [14]. Furthermore, those authors were able to identify parameters that were associated with higher recovery rate: age < 50 years, non-ischemic cardiomyopathy (NICM), time from cardiac diagnosis < 2 years, absence of ICD, creatinine < 1.2 mg/dl, and LVEDD < 6.5 cm (c-index 0.85; p < 0.0001) [14].

Other investigators reported higher rates of myocardial recovery in specific patient populations when designated myocardial recovery protocols were used. Birks et al. reported 73.3% recovery by using a protocol of aggressive neurohormonal blockade with the beta agonist clenbuterol in patients supported with pulsatile pump (HeartMate XVE). However, patients in this study were young and had a short HF duration prior to LVAD making these results less generalizable. Several years later, the same group reported a 63% explantation rate among patients supported with continuous-flow LVAD (HeartMate II) using a similar medical protocol [15, 16]. Though, when the same study was conducted in the USA as a multicenter study, the investigators were not able to replicate those results [17].

Multiple investigators continue to report varying success rates of myocardial recovery utilizing different medical protocols [18] and as such a systematic multicenter non-randomized longitudinal study to assess myocardial recovery was designed. The RESTAGE-HF (Remission From Stage D Heart Failure) (NCT01774656) has now completed recruitment and interim analysis had shown findings supportive of high rate of clinical myocardial recovery 36% with LVAD explantation in highly selected patients [19]. The results of the study will be reported in the next few months.

Myocardial Changes After Mechanical Unloading

On the molecular level, mechanical unloading following LVAD therapy has been shown to promote changes in myocardial structural and gene expression. While the changes in the molecular and cellular substrate are beyond the scope of this review and have been extensively discussed in prior reviews [20], a consistent theme has been the persistent abnormalities in the molecular and cellular function in the setting of reverse remodeling. To this end, the concept of “myocardial remission” was introduced to distinguish improvement in ventricular function from the complete restoration of the pathogenic molecular changes of heart failure, including freedom from the clinical cardiovascular events seen in heart failure. This is highlighted by studies of patients with “recovery” of LV function and persistent abnormalities in biomarkers and increased risk for recurrent clinical cardiovascular events [21, 22, 23].

The clinical question remains how patients with LVAD and potential remission of heart failure could be better identified and thus selected for explantation. Biomarkers of heart failure would be attractive non-invasive tools since they might enable insight into molecular pathophysiology of HF with serial assessment to document improvement of molecular pathways following unloading with LVAD therapy [24]. However, most available HF biomarkers have not been tested in patients with end-stage HF, and the direction and magnitude of expected changes in biomarker levels after LVAD reflecting hemodynamic improvement, mechanical unloading reflecting reduction in the degree of dysfunction in molecular pathways, is uncertain at this time [24].

Heart Failure Biomarkers

Peripheral blood heart failure biomarkers have been shown to predict HF and future events, assess severity, and guide therapy in acute and chronic stable HF [25].

A recent study enrolling 2516 patients with worsening heart failure from the BIOSTAT-CHF (Biology Study to Tailored Treatment in Chronic Heart Failure) showed a reduction in hospitalization and death when using a biomarker-guided strategy of up-titrating HF medications compared to a hypothetical scenario in which all patients were successfully up-titrated [26•].

Heart failure biomarkers can be categorized following the pathway they represent. A summary is shown in Fig. 1 [27, 28]:
  • Myocardial overload/stretch and injury

  • Neurohormonal activation

  • Adverse remodeling/fibrosis

  • Markers of co-morbidities such as creatinine and anemia markers

Fig. 1

The systemic effects of heart failure include a large variety of pathways and HF biomarkers can be categorized accordingly. While neurohormonal activation and cardio-renal interaction are some of the hallmarks of HF, further systemic effects such as inflammation, increased oxidative stress, anemia, and hepatic effects are additional essential components of picturing HF as a systemic disease affecting multiple organ systems. Lastly, the effects on the failing myocardium can be classified into myocardial stretch, myocardial injury, and lastly adverse remodeling and fibrosis. ANP, atrial natriuretic peptide; APO, apoptosis antigen; BUN, blood urea nitrogen; CK-MB, creatinine kinase-MB fraction; CRP, c-reactive protein; GDF-15, growth differentiation factor; HF, heart failure; ICAM, intercellular adhesion molecule; KIM1, kidney injury molecule-1; MMPs, matrix metalloproteinases; MR-proADM, mid-regional pro adrenomedullin; NAG, N-acetyl-β-d-glucosaminidase; NT-proBNP, N-terminal pro B-type natriuretic peptide; NGAL, neutrophil gelatinase-associated lipocalin; RAAS, renin-angiotensin-aldosterone system; TIMPs, tissue inhibitors of metalloproteinases; TNF-α, tumor necrosis factor alpha

A full review on biomarkers in heart failure is beyond the scope of this review and has been discussed elsewhere [25].

Markers of Congestion Overload and Myocardial Stretch

Brain Natriuretic Peptides

B-type natriuretic peptide (BNP) gene transcription is induced following end-diastolic volume or pressure overload. BNP and its cleavage equivalent N-terminal pro B-type natriuretic peptide (NT-proBNP) are directly released into the circulation leading to diuresis and inhibition of the renin-angiotensin-aldosterone system (RAAS) [29, 30]. Both NT-proBNP and BNP reflect heart failure severity, and response to therapy, and are well-established predictors of de novo heart failure diagnosis and outcome [31, 32, 33]. Admission levels of BNP and NT-proBNP in acute decompensated heart failure as well as serial measurements in chronic heart failure have been shown to be associated with short- and long-term mortality [34, 35, 36]. Both markers decrease with heart failure therapy and rising levels have a poor prognosis [36]. However, the recently published GUIDE-IT trial examining the role of a BNP and NT-proBNP-guided strategy to manage high-risk HFrEF (n 446) patients did not show a benefit over standard of care (n 448) to improve outcome including time to first hospitalization and cardiovascular mortality [37]. These disappointing results differ from previous studies; among other considerations, this might have been related to the high-risk patient population with more severe heart failure, complicated by hypotension and azotemia limiting the ability to aggressively up-titrate medical therapy in response to NT-proBNP levels [37].

In patients with LVADs, serum levels of natriuretic peptides have been shown to decrease following myocardial unloading [24, 38, 39].

In a small study of 24 patients, serial measurements of both ANP and BNP demonstrated that the magnitude of BNP/ANP downregulation was dependent on LVAD type but was seen in all types of assist devices reaching normal levels in a small number of patients [38].

Circulating BNP levels (n = 17) as well as mRNA expression were measured in cardiac biopsy specimens of 27 patients before and after LVAD implantation. BNP plasma levels significantly decreased 3 months after LVAD implantation. This decrease in plasma levels was accompanied by a significant decrease of myocardial mRNA expression. Interestingly, BNP was found to be expressed not only by cardiomyocytes but also by endothelial cells, T cells, and macrophages [39]. Among patients with proven myocardial recovery, lower BNP levels were measured; however, BNP has not been evaluated as a predictor of outcome in this study [14].

Recently, Ahmad et al. described changes in a broad panel of biomarkers following LVAD in 37 patients including NT-proBNP [24]. Levels were measured prior to and a median of 136 days post-LVAD implantation. All biomarkers but neutrophil gelatinase-associated lipocalin (NGAL) decreased significantly post-LVAD but all levels remained significantly abnormal. Changes of HF biomarkers were also assessed based on prespecified changes in serial NT-proBNP levels, and, interestingly, when stratified for NT-proBNP levels, only the change of galectin-3 levels was significant post-LVAD [24].

The authors point out that despite the advanced stage of HF with high NT-proBNP levels in the study cohort, these patients had normal or barely altered concentrations of more common laboratory measurements (such as sodium, creatinine, BUN, and RDW) which are known to have prognostic significance in heart failure [40]. This finding underlines the need for broader use of more sensitive biomarkers over standard clinical parameters when assessing advanced heart failure patients and as a potential monitoring tool for advanced heart failure therapies [24, 41] (Table 1).
Table 1

Novel protein biomarkers in LVAD studies


Study design

Major finding

Potential implication


[24, 42•]

Serial ST2 serum measurements at pre- and 1, 3 and 6 months post-LVAD (n = 38) [42•]

Serum levels pre and a median of 136 days (IQR 94 to 180) post-LVAD (n = 37) [24]

ST2 levels were significantly elevated in end-stage HF prior LVAD implantation and decreased post-LVAD to normal levels within 3 months [42]

ST2 levels decreased significantly post-LVAD [24]

ST2 may be useful as a biomarker to monitor therapy in end-stage heart failure patients


[24, 43]

Galectin-3 levels pre and 1 month post-LVAD (n = 40) or TAH (n = 15) [43]

Galectin-3 level stratified for prespecified pro-BNP reduction (n = 37) pre and a median of 136 days (IQR 94 to 180) post-LVAD [24]

No significant change in expression pre- and post-LVAD. Patients who did not survive VAD due to MOF had significantly higher plasma concentrations of galectin-3 at the time of LVAD implant [43]

Greater significant reduction in galectin-3 was seen when stratified for pro-BNP with prespecified reduction post-LVAD [24]

No significant change with unloading as a single marker but potential additive information when assessed with other biomarkers



Serum and myocardial expression in NICM pre, 1, 3, and 6 months post-LVAD and at HT or VAD explant

(n = 30)

At 1 month post-LVAD, serum levels of GDF-15 were significantly decreased.

No difference in serum levels per LVAD strategies for BTT (n = 25) and BTR (n = 5) but observation limited by small sample size

Potential tool for monitoring post-LVAD but so far has not shown ability to discriminate between BTR and BTT


[24, 45]

Serum levels in stable HF (n = 40), LVAD implantation (n = 40), HT (n = 40), and 24 controls [45]

Serum levels pre and a median of 136 days (IQR 94 to 180) post-LVAD (n = 37) [24]

NGAL levels increase with the severity of HF and decrease following LVAD. Higher in RV failure post-LVAD and higher in irreversible renal dysfunction [45]

NGAL did not decrease post-LVAD despite normalization of serum creatinine levels [24]

NGAL might be of value in prediction of RV failure post-LVAD and as a novel biomarker of renal dysfunction in patients with HF pending further clinical studies

BTR, bridge to recovery; BTT, bridge to transplantation; GDF-15, growth differentiation factor-15; HF, heart failure; HT, heart transplantation; IQR, interquartile range; LVAD, left ventricular assist device; MOF, multiple-organ failure; NGAL, neutrophil gelatinase-associated lipocalin; NICM, non-ischemic cardiomyopathy

Markers of Fibrosis


ST2 is a member of the interleukin 1 receptor family with soluble and membrane-bound isoforms [46]. IL-33 is the functional ligand and the IL-33/ST2 signaling and is protective against myocardial hypertrophy and fibrosis in response to pressure overload [47]. Soluble ST2 acts as a decoy receptor for IL-33 preventing this interaction and resulting in loss of cardioprotective effects of IL-33 in heart failure. The vascular endothelium is likely the predominant source of soluble ST2, rather than the human myocardium as initially described; however, results remain controversial [48]. ST2 levels have been shown to be independent risk factors for mortality in chronic and acute decompensated heart failure and levels have been shown to decrease with treatment [49, 50, 51].

Data from the recently published TRIUMPH trial assessed the predictive value of frequently measured ST2 and NT-Pro-BNP levels in 496 patients with acute HF over 1 year follow-up for a primary composite endpoint of all-cause mortality and HF re-hospitalization. After adjustment for clinical factors and NT-proBNP, baseline ST2 was associated with an increased risk of the primary endpoint; additionally, ST2 levels appeared to be rising several weeks before the time of the primary endpoint [52]. ST2 was identified as a strong predictor in acute decompensated HF independent of serial measured NT-proBNP. Thus, measuring ST2 could provide additional benefit to NT-proBNP assessment.

In an LVAD study, serial serum measurements of ST2 were performed at pre-implantation and 1, 3, and 6 months after LVAD implantation in 38 patients. As reported previously, ST2 levels were significantly elevated in end-stage HF prior to LVAD implantation (74.2 ng/ml (IQR 54.7–116.9; normal < 30 ng/ml)) and decreased substantially during LVAD support, to 29.5 ng/ml (IQR 24.7–46.6) (p < 0.001) to normal levels within 3 months in most patients. This suggests that even in patients with end-stage HF, ST2 may be used as a biomarker to monitor therapy [42•].

ST2 might be seen as the new gold standard biomarker for prognosis and monitoring in heart failure and has now been approved by the FDA and was included in the 2017 American College of Cardiology/American Heart Association update of HF guidelines [53, 54]. However, data on the value of ST2 in assessing for myocardial recovery in LVAD patients is sparse but promising at this point and the fact that ST2 levels do change with medical management could be a helpful asset [42•, 55, 56, 57]. The predictive value of ST2 now needs to be evaluated in large clinical trials [54].


Galectin-3 is secreted by activated cardiac macrophages and has pro-fibrotic properties implied in hypertrophy and adverse remodeling. Serum concentrations are increased in HF patients and have been shown to be associated with adverse outcomes in chronic heart failure [58, 59].

The PROTECT trial enrolling 151 patients with HF assessed serial galectin-3 levels. Time spent below serum levels of 20 ng/ml was an independent predictor of a lower cardiovascular event rate and increase of LV function even when adjusted for NT-proBNP, and renal function. Furthermore, galectin-3 levels at 6 months added prognostic value beyond the baseline level. Importantly, there were no significant effects of medications on galectin-3 levels [60].

Milting et al. described significantly elevated concentrations of galactin-3 at the time of LVAD implantation but no change by mechanical unloading or removal of the failing ventricles in the setting of total artificial heart. However, patients who did not survive LVAD due to multiple-organ failure (MOF) had significantly higher plasma concentrations of galectin-3 at the time of LVAD implantation as compared with those patients who were successfully bridged to transplantation [43].

ST2 has recently been found to be superior to galectin-3 [61], and importantly in contrast to galectin-3, ST2 levels change in response to medical management [56, 57].

Growth Differentiation Factor-15

Growth differentiation factor-15 (GDF-15) is a protein of the transforming growth factor beta superfamily and is emerging as a biomarker of heart failure, fibrosis, and potentially cardiac remodeling [62, 63, 64]. In a report of 30 patients with NICM, circulating levels and myocardial protein and mRNA expression of GDF-15 were analyzed before and 1, 3, and 6 months post-LVAD implantation as well as at the time of heart transplantation or LVAD explantation. One month post-LVAD implantation, serum levels of GDF-15 were significantly decreased compared with pre-implantation levels and remained stable thereafter. Furthermore, 96% of the end-stage HF patients were found to have elevated GDF-15 levels prior to LVAD, while only 25% had elevated level, 6 months following LVAD implantation.

Serum GDF-15 significantly correlated with kidney function and AST. Interestingly, serum GDF-15 levels also correlated with the severity of myocardial fibrosis but myocardial expression of GDF-15 was hardly detectable, suggesting that the myocardium is not a relevant source of GDF-15 production in these patients [44]. Importantly, there was no difference in serum levels of GDF-15 between patients with LVAD strategies for bridge to transplantation (BTT) and BTR. Thus, the authors concluded that it is unlikely that GDF-15 can identify those patients that will demonstrate substantial recovery; however, this observation is limited by the small sample size of 25 BTT versus 5 BTR patients [44].

Inflammatory Markers

Changes of CRP concentrations post-LVAD have been infrequently studied. One report has shown persistently elevated CRP levels following LVAD and was shown to exacerbate end-organ dysfunction [65]. Ahmad at et al. described decreasing CRP levels post-LVAD [24].

Grosman-Rimon et al. studied plasma levels of chemokines, cytokines, and inflammatory markers in 18 LVAD recipients, 14 heart failure patients waiting for LVAD placement, and 14 healthy control subjects. Levels of granulocyte-macrophage colony-stimulating factor, macrophage inflammatory proteins-1β, and macrophage-derived chemokine were significantly higher in the LVAD group compared with both the heart failure and the healthy control groups. CRP, interferon gamma-induced protein 10, monocyte chemotactic protein 1, and interleukin 8 levels were significantly higher in both the LVAD and heart failure groups compared to those in the control, but no significant differences were observed between the LVAD recipients and the heart failure patients. However, it is unknown if these elevated markers of inflammation have clinical implication [66]. Our group recently showed elevated levels of TNF-α in LVAD patients contributing to vascular destabilization via induction of pericyte apoptosis and suppression of angiopoietin-1 expression as well as higher expression of tissue factor. Higher levels of TNF-α were associated with a higher risk of non-surgical bleeding. TNF-α might be a central regulator of LVAD-related angiodysplasia [67•].

Neutrophil Gelatinase-Associated Lipocalin

Neutrophil gelatinase-associated lipocalin (NGAL) is a small iron-binding protein and was originally characterized in extracts and secretions from human neutrophils [68]. It is secreted at a baseline normal level from renal tubular cells with rapid increase during acute kidney injury and heart failure [69, 70]. In previous studies of post-myocardial infarction and HF as well as chronic HF, NGAL correlated with NYHA class and was associated with worsening renal function superior to BNP, creatinine, eGFR, and cystatin C to predict events and mortality [69, 71, 72, 73].

Pronschinske et al. assessed NGAL and cystatin C both in HF and after LVAD placement (n = 40). NGAL and cystatin C were elevated in patients with stable HF when compared to controls; NGAL increases with the severity of HF and decreased following LVAD implantation and hemodynamic improvement. NGAL was higher in patients developing irreversible renal dysfunction and correlated with eGFR. In this trial, NGAL outperformed established markers of renal function as well as cystatin C, but the underlying biologic mechanisms explaining this advantage are unclear. The authors introduce a cutoff of 200 ng/ml, representing the level at which it is 88.9% certain that a patient’s renal function will not improve following LVAD. Interestingly, NGAL was higher in those patients who developed right heart failure after LVAD implantation. NGAL level higher than 100 ng/ml was associated with right ventricular (RV) failure in 93.3% of the cases, while NGAL lower than 100 ng/ml was associated with only a 40.0% chance of developing RV failure [45]. However, in a different study, NGAL remained abnormal post-LVAD despite normalization of serum creatinine levels. The authors raised the question if some aspects of renal function are not adequately captured by creatinine clearance alone [24].

It remains to be clarified if NGAL could be a direct marker of cardiac remodeling and HF severity or if it is mostly a marker or renal function affected by cardiac function? [69]. Additionally, the value of NGAL in prediction of RV failure would need to be assessed in multicenter studies with confirmatory validation [74]. The role of NGAL in myocardial recovery is unknown at this time.


MicroRNAs are short, non-coding RNAs that have been shown to be epigenetic regulators of stress responses in the heart via microRNA degradation or inhibition of protein translation. Despite being single-stranded RNA, microRNAs have demonstrated stability in both tissues and serum thus prompting investigation into the role of microRNAs as biomarkers.

Wang et al. assessed changes in plasma microRNA levels following LVAD implantation according to prespecified changes in the serially measured biomarkers galectin-3, NT-proBNP, and ST2. In one third of the cases, biomarkers improved, which was associated with an upregulation of a majority of microRNAs [75]. In a study to investigate microRNA signatures in the setting of LVAD support, Akat et al. analyzed the cardiac-specific microRNA expression patterns in both myocardial tissue and serum in healthy individuals, in patients with stable heart failure, and in LVAD recipients (total n = 47). Healthy controls and stable heart failure patients demonstrated a low level of circulating levels of cardiac-specific miRNAs (< 0.1%) among all circulating mRNAs in serum. For the patients undergoing LVAD implant, serum levels of the cardiac-specific miR-208a, miR-208b, and miR-499 and the muscle-specific miR-1-1 and mir-133b increased by 140-fold (> 1%). Interestingly, serum levels of these cardiac-specific miRNAs declined to nearly normal during the period of LVAD support [76]. Whether this signature is a reflection of mechanical unloading or more simply a marker of myocardial injury remains unanswered as these changes correlated with other cardiac biomarker of injury such as troponin I, yet did not correlate with BNP. Further studies of circulating miRNA expression patterns with rigorous assessments of reverse remodeling are warranted. LVAD therapy provides an opportunity to study changes in myocardial tissue and therefore a chance to understand the pathways that may promote recovery. These changes as reflected in serum may then provide powerful insight into the response to mechanical unloading and the potential to recover native ventricular function.

Can HF Biomarkers Reflect Myocardial Remission/Recovery? Potential Use of HF Biomarkers in LVAD

Several studies have shown that HF biomarkers change in response to neurohormonal blockade in chronic HF; however, it remains to be established if these findings are applicable to an end-stage heart failure population supported with LVAD [31, 32, 33, 49, 50, 51].

The field shows several promising developments, the most intriguing development possibly seen with the establishment of ST2 as a new biomarker. Nonetheless, not all studies assessing the response of HF biomarkers post-LVAD and/or initiation of neurohormonal blockade reported a measurable effect. At this time, no peripherally assessed biomarker reliably reflects myocardial recovery or remission. However, heart failure biomarkers might be helpful to assess response to medical management or adjustment in LVAD settings (such as LVAD speed) in these patients. Especially since centers with reported high rates of myocardial recovery post-LVAD report aggressive up-titration of neurohormonal blockade [77], the INTERMACS registry study revealed significantly higher likelihood of recovery with medical management [14]. Thus, the ability of HF biomarkers to assess response to neurohormonal blockade could be a great asset.

A few HF biomarkers when studied in the LVAD population were associated with outcomes. Galectin-3 levels at the time of LVAD implantation were significantly higher in patients developing MOF compared to those successfully bridged to transplant [43].

NGAL levels were higher in patients with irreversible kidney failure and right ventricular failure post-LVAD [45]. When compared between patients with LVAD for BTR or BTT, no difference in serum levels of GDF-15 was found; in this study, the authors concluded that it is unlikely that GDF-15 can identify those patients that will demonstrate substantial recovery [44]. Novel biomarkers are summarized in the table.


The development and enhanced understanding of HF biomarkers in monitoring myocardial and neurohormonal activation response to mechanical unloading are promising and deserve further investigation in prospective studies with clearly defined endpoints, especially with the question of response to medical management and changes in LVAD settings. However, at this time, there is insufficient evidence to select a single or a set of heart failure biomarkers to reliably identify patients bridged to recovery for LVAD explantation.


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Katz AM. Maladaptive growth in the failing heart: the cardiomyopathy of overload. Cardiovasc Drugs Ther. 2002;16(3):245–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.CrossRefPubMedGoogle Scholar
  3. 3.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77.CrossRefPubMedGoogle Scholar
  4. 4.
    Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J. 2000;139(6):1081–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, Kitaoka H, et al. Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2011;107(7):1065–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.CrossRefPubMedGoogle Scholar
  7. 7.
    Drakos SG, Kfoury AG, Hammond EH, Reid BB, Revelo MP, Rasmusson BY, et al. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol. 2010;56(5):382–91.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Farris SD, Don C, Helterline D, Costa C, Plummer T, Steffes S, et al. Cell-specific pathways supporting persistent fibrosis in heart failure. J Am Coll Cardiol. 2017;70(3):344–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Diakos NA, Selzman CH, Sachse FB, Stehlik J, Kfoury AG, Wever-Pinzon O, et al. Myocardial atrophy and chronic mechanical unloading of the failing human heart: implications for cardiac assist device-induced myocardial recovery. J Am Coll Cardiol. 2014;64(15):1602–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Diakos NA, Navankasattusas S, Abel ED, Rutter J, McCreath L, Ferrin P, et al. Evidence of glycolysis up-regulation and pyruvate mitochondrial oxidation mismatch during mechanical unloading of the failing human heart: implications for cardiac reloading and conditioning. JACC Basic Transl Sci. 2016;1(6):432–44.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Margulies KB, Matiwala S, Cornejo C, Olsen H, Craven WA, Bednarik D. Mixed messages: transcription patterns in failing and recovering human myocardium. Circ Res. 2005;96(5):592–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Drakos SG, Kfoury AG, Stehlik J, Selzman CH, Reid BB, Terrovitis JV, et al. Bridge to recovery: understanding the disconnect between clinical and biological outcomes. Circulation. 2012;126(2):230–41.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Topkara VK, Garan AR, Fine B, Godier-Furnemont AF, Breskin A, Cagliostro B, Yuzefpolskaya M, Takeda K, Takayama H, Mancini DM, et al. Myocardial recovery in patients receiving contemporary left ventricular assist devices: results from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Circ Heart Fail. 2016;9(7):e00315.Google Scholar
  14. 14.
    Wever-Pinzon O, Drakos SG, McKellar SH, Horne BD, Caine WT, Kfoury AG, et al. Cardiac recovery during long-term left ventricular assist device support. J Am Coll Cardiol. 2016;68(14):1540–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355(18):1873–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123(4):381–90.CrossRefPubMedGoogle Scholar
  17. 17.
    Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD, et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation. 2007;115(19):2497–505.CrossRefPubMedGoogle Scholar
  18. 18.
    Drakos SG, Mehra MR. Clinical myocardial recovery during long-term mechanical support in advanced heart failure: insights into moving the field forward. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2016;35(4):413–20.CrossRefGoogle Scholar
  19. 19.
    Birks EJ REPS, et al. Poster S4026. REmission from Stage D Heart Failure (RESTAGE-HF): interim results and insights from a prospective multi-center non-randomized study of myocardial recovery using LVADs. Presented at: 2016 American Heart Association Scientific Sessions November 12–16, 2016; New Orleans, LA. 2016.Google Scholar
  20. 20.
    Kim GH, Uriel N, Burkhoff D. Reverse remodelling and myocardial recovery in heart failure. Nat Rev Cardiol. 2017;15:83–96.CrossRefPubMedGoogle Scholar
  21. 21.
    Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation. 2014;129(23):2380–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    de Groote P, Fertin M, Duva Pentiah A, Goeminne C, Lamblin N, Bauters C. Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after beta-blocker therapy. Circ Heart Fail. 2014;7(3):434–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Uriel N, Kim G, Burkhoff D. Myocardial recovery after LVAD implantation: a vision or simply an illusion? J Am Coll Cardiol. 2017;70(3):355–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Ahmad T, Wang T, O'Brien EC, Samsky MD, Pura JA, Lokhnygina Y, et al. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. JACC Heart Fail. 2015;3(1):30–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054–e91.CrossRefPubMedGoogle Scholar
  26. 26.
    • Ouwerkerk W, Zwinderman AH, Ng LL, Demissei B, Hillege HL, Zannad F, et al. Biomarker-guided versus guideline-based treatment of patients with heart failure: results from BIOSTAT-CHF. J Am Coll Cardiol. 2018;71(4):386–98. This article points out a potential benefit of biomarker-guided up-titration of heart failure therapy CrossRefPubMedGoogle Scholar
  27. 27.
    Ahmad T, Fiuzat M, Felker GM, O’Connor C. Novel biomarkers in chronic heart failure. Nat Rev Cardiol. 2012;9(6):347–59.CrossRefPubMedGoogle Scholar
  28. 28.
    Ibrahim NE, Gaggin HK, Konstam MA, Januzzi JL Jr. Established and emerging roles of biomarkers in heart failure clinical trials. Circ Heart Fail. 2016;9(9):e002528.CrossRefPubMedGoogle Scholar
  29. 29.
    Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest. 1995;96(3):1280–7.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47(4):742–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948–54.CrossRefPubMedGoogle Scholar
  33. 33.
    Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58(18):1881–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Januzzi JL Jr, Sakhuja R, O'Donoghue M, Baggish AL, Anwaruddin S, Chae CU, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166(3):315–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997–1003.CrossRefPubMedGoogle Scholar
  37. 37.
    Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017;318(8):713–20.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Milting H, A ELB, Kassner A, Fey O, Sarnowski P, Arusoglu L, et al. The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricular assist device support reveals differences among device types. J Heart Lung Transplant. 2001;20(9):949–55.CrossRefPubMedGoogle Scholar
  39. 39.
    Bruggink AH, de Jonge N, van Oosterhout MF, Van Wichen DF, de Koning E, Lahpor JR, et al. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. J Heart Lung Transplant. 2006;25(2):174–80.CrossRefPubMedGoogle Scholar
  40. 40.
    Halkar M, Tang WH. Incorporating common biomarkers into the clinical management of heart failure. Current heart failure reports. 2013;10(4):450–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Zilinski JL, Shah RV, Gaggin HK, Gantzer ML, Wang TJ, Januzzi JL. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care. 2012;16(4):R135.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    • Tseng CCH MM, Gaykema L, Chamuleau SA, de Jonge N. Soluble ST2 levels in end-stage heart failure and during LVAD support. J Heart Lung Transplant. 2016;35(4):S13. This article describes changes of ST2 following LVAD CrossRefGoogle Scholar
  43. 43.
    Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008;27(6):589–96.CrossRefPubMedGoogle Scholar
  44. 44.
    Lok SI, Winkens B, Goldschmeding R, van Geffen AJ, Nous FM, van Kuik J, et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail. 2012;14(11):1249–56.CrossRefPubMedGoogle Scholar
  45. 45.
    Pronschinske KB, Qiu S, Wu C, Kato TS, Khawaja T, Takayama H, et al. Neutrophil gelatinase-associated lipocalin and cystatin C for the prediction of clinical events in patients with advanced heart failure and after ventricular assist device placement. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(12):1215–22.CrossRefGoogle Scholar
  46. 46.
    Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–90.CrossRefPubMedGoogle Scholar
  47. 47.
    Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538–49.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008;52(25):2166–74.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4(2):180–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Aimo A, Vergaro G, Passino C, Ripoli A, Ky B, Miller WL, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart failure. 2017;5(4):280–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013;168(3):2186–94.CrossRefPubMedGoogle Scholar
  52. 52.
    van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Orsel JG, et al. Prognostic value of serial ST2 measurements in patients with acute heart failure. J Am Coll Cardiol. 2017;70(19):2378–88.CrossRefPubMedGoogle Scholar
  53. 53.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017;23(8):628–51.CrossRefPubMedGoogle Scholar
  54. 54.
    Bayes-Genis A, Nunez J, Lupon J. Soluble ST2 for prognosis and monitoring in heart failure: the new gold standard? J Am Coll Cardiol. 2017;70(19):2389–92.CrossRefPubMedGoogle Scholar
  55. 55.
    Caselli C, D'Amico A, Ragusa R, Caruso R, Prescimone T, Cabiati M, et al. IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? Mediat Inflamm. 2013;2013:498703.CrossRefGoogle Scholar
  56. 56.
    Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL Jr. Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6(6):1206–13.CrossRefPubMedGoogle Scholar
  57. 57.
    Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–50.CrossRefPubMedGoogle Scholar
  58. 58.
    van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217–24.CrossRefPubMedGoogle Scholar
  59. 59.
    de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1):60–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013;15(10):1157–63.CrossRefPubMedGoogle Scholar
  61. 61.
    Bayes-Genis A, de Antonio M, Vila J, Penafiel J, Galan A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;63(2):158–66.CrossRefPubMedGoogle Scholar
  62. 62.
    Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(11):1054–60.CrossRefPubMedGoogle Scholar
  63. 63.
    Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122(14):1387–95.CrossRefPubMedGoogle Scholar
  64. 64.
    Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. Mod Rheumatol. 2012;22(5):668–75.CrossRefPubMedGoogle Scholar
  65. 65.
    Masai T, Sawa Y, Ohtake S, Nishida T, Nishimura M, Fukushima N, et al. Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg. 2002;73(2):549–55.CrossRefPubMedGoogle Scholar
  66. 66.
    Grosman-Rimon L, McDonald MA, Jacobs I, Tumiati LC, Pollock Bar-Ziv S, Shogilev DJ, et al. Markers of inflammation in recipients of continuous-flow left ventricular assist devices. ASAIO J. 2014;60(6):657–63.CrossRefPubMedGoogle Scholar
  67. 67.
    • Tabit CE, Coplan MJ, Chen P, Jeevanandam V, Uriel N, Liao JK. Tumor necrosis factor-alpha levels and non-surgical bleeding in continuous-flow left ventricular assist devices. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2018;37(1):107–15. This article implies elevated TNF-alpha levels post-LVAD in non-surgical bleeding CrossRefGoogle Scholar
  68. 68.
    Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993;268(14):10425–32.PubMedGoogle Scholar
  69. 69.
    Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. Journal of the American Society of Nephrology : JASN. 2003;14(10):2534–43.CrossRefPubMedGoogle Scholar
  70. 70.
    Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009;30(10):1229–36.CrossRefPubMedGoogle Scholar
  71. 71.
    Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, et al. Tubular damage and worsening renal function in chronic heart failure. JACC Heart failure. 2013;1(5):417–24.CrossRefPubMedGoogle Scholar
  72. 72.
    Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation along with B-type NaTriuretic peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011;13(8):846–51.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    van Deursen VM, Damman K, Voors AA, van der Wal MH, Jaarsma T, van Veldhuisen DJ, et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail. 2014;7(1):35–42.CrossRefPubMedGoogle Scholar
  74. 74.
    Lund LH, Gabrielsen A. Biomarkers in advanced heart failure—pathophysiology leading to clinical use? The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(12):1213–4.CrossRefGoogle Scholar
  75. 75.
    Wang T, O'Brien EC, Rogers JG, Jacoby DL, Chen ME, Testani JM, et al. Plasma levels of microRNA-155 are upregulated with long-term left ventricular assist device support. ASAIO J. 2017;63(5):536–41.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Akat KM, Mooremgriff D, Morozov P, Brown M, Gogakos T, Correa Da Rosa J, et al. Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proc Natl Acad Sci U S A. 2014;111(30):11151–6.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Patel SR, Saeed O, Murthy S, Bhatia V, Shin JJ, Wang D, et al. Combining neurohormonal blockade with continuous-flow left ventricular assist device support for myocardial recovery: a single-arm prospective study. J Heart Lung Transplant. 2013;32(3):305–12.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Luise Holzhauser
    • 1
  • Gene Kim
    • 1
  • Gabriel Sayer
    • 1
  • Nir Uriel
    • 1
  1. 1.Department of Medicine, Division of CardiologyUniversity of ChicagoChicagoUSA

Personalised recommendations